Literature DB >> 20713932

Robotic posterior retroperitoneal adrenalectomy: operative technique.

Eren Berber1, Jamie Mitchell, Mira Milas, Allan Siperstein.   

Abstract

OBJECTIVE: To describe a robotic technique for posterior retroperitoneal (PR) adrenalectomy.
DESIGN: Prospective study.
SETTING: Academic hospital. PATIENTS: Twenty-three patients had robotic adrenalectomy within a year. Of these, 8 cases were done using a PR approach. MAIN OUTCOME MEASURES: Feasibility of the robotic approach, patient and tumor characteristics, operative time, and complications.
RESULTS: There were 5 women and 3 men (mean age, 52 years). There were no conversions to laparoscopic or open surgery. Pathology included benign adrenocortical adenoma in 3 patients, aldosteronoma in 2, and pheochromocytoma, subclinical Cushing syndrome, and lymphangioma in 1 patient each. The right and left sides were each involved in 4 patients. The mean (SD) tumor size was 2.9 (1.7) cm. The procedures were done using 3 trocars and 5-mm robotic instruments. The mean (SD) operative time was 214.8 (40.8) minutes; docking time, 21.7 (16.6) minutes; and console time, 97.1 (24.2) minutes. Estimated blood loss was 24 (35) mL. All patients were discharged to home in 24 hours. There were no complications. Subjectively, the dissection was felt to be easier with the robotic technique compared with the laparoscopic approach owing to the improved dexterity of the instruments.
CONCLUSIONS: To our knowledge, this is the first article describing robotic PR adrenalectomy, and we have demonstrated the technique to be feasible and safe. Owing to the limitations of a conventional laparoscopic PR approach, we believe that use of the robot is a refinement of the technique.

Entities:  

Mesh:

Year:  2010        PMID: 20713932     DOI: 10.1001/archsurg.2010.148

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  23 in total

Review 1.  [Minimally invasive adrenal gland surgery. Transperitoneal or retroperitoneal approach?].

Authors:  M K Walz
Journal:  Chirurg       Date:  2012-06       Impact factor: 0.955

Review 2.  Robotic endocrine surgery: state of the art.

Authors:  Halit Eren Taskin; Naciye Cigdem Arslan; Shamil Aliyev; Eren Berber
Journal:  World J Surg       Date:  2013-12       Impact factor: 3.352

3.  SAGES guidelines for minimally invasive treatment of adrenal pathology.

Authors:  Dimitrios Stefanidis; Melanie Goldfarb; Kent W Kercher; William W Hope; William Richardson; Robert D Fanelli
Journal:  Surg Endosc       Date:  2013-09-10       Impact factor: 4.584

4.  Robotic adrenalectomy by an open surgeon: are outcomes different?

Authors:  Shankar R Raman; Emil Shakov; Nino Carnevale; Anusak Yiengpruksawan
Journal:  J Robot Surg       Date:  2011-07-08

5.  The early results of our initial experience with robotic adrenalectomy.

Authors:  Cevher Akarsu; Ahmet Cem Dural; Burak Kankaya; Muhammet Ferhat Çelik; Osman Köneş; Meral Mert; Mustafa Uygar Kalaycı; Halil Alış
Journal:  Ulus Cerrahi Derg       Date:  2014-03-01

6.  Robotic retroperitoneoscopic adrenalectomy: useful modifications of the described posterior approach.

Authors:  Zuliang Feng; Michael P Feng; Jessica W Levine; Carmen C Solórzano
Journal:  J Robot Surg       Date:  2017-01-02

Review 7.  Surgical management of adrenocortical tumours.

Authors:  Barbra S Miller; Gerard M Doherty
Journal:  Nat Rev Endocrinol       Date:  2014-03-18       Impact factor: 43.330

Review 8.  Robotic endocrine surgery: technical details and review of the literature.

Authors:  Volkan Genc; Orhan Agcaoglu; Eren Berber
Journal:  J Robot Surg       Date:  2011-07-31

9.  Robotic surgery for primary hyperparathyroidism.

Authors:  Georgios Karagkounis; Duygu Derya Uzun; David P Mason; Sudish C Murthy; Eren Berber
Journal:  Surg Endosc       Date:  2014-04-26       Impact factor: 4.584

10.  Robotic versus laparoscopic adrenalectomy in obese patients.

Authors:  Erol Aksoy; Halit Eren Taskin; Shamil Aliyev; Jamie Mitchell; Allan Siperstein; Eren Berber
Journal:  Surg Endosc       Date:  2012-10-17       Impact factor: 4.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.